"All I want for christmas is two": The advent of novel fixed-combination inhalers for COPD and outlook for 2014

Advances in Therapy

Volumn 30, Issue 12, 2013, Pages 1033-1037

  Beeh, Kai M ^a  

^a Institut fur Atemwegsforschung INSAF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACLIDINIUM BROMIDE PLUS FORMOTEROL; ACLIFORM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE FUROATE PLUS VILANTEROL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; BENZYL ALCOHOL DERIVATIVE; CHLOROBENZENE; DELAYED RELEASE FORMULATION; DRUG COMBINATION; GLYCOPYRRONIUM BROMIDE; VILANTEROL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DRUG RESEARCH; HIGH RISK PATIENT; HUMAN; INHALER; MONOTHERAPY; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION; DRUG COMBINATION; FORECASTING; INHALATIONAL DRUG ADMINISTRATION; NEBULIZER; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADMINISTRATION, INHALATION; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FORECASTING; GLYCOPYRROLATE; HUMANS; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 84890549890     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-013-0075-7     Document Type: Review

References (19)

1. ® ELLIPTA™ Now available in the US for the treatment of COPD. Available at: http://investor.theravance.com/releasedetail.cfm?ReleaseID=801611. Last accessed November 15, 2013.
2. Novartis. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan. Available at: www.novartis.com/newsroom/media-releases/en/ 2013/1730580.shtml. Last accessed November 15, 2013.
3. ®. FDA Advisory Committee Recommends Approval in US of umeclidinium/vilanterol for the treatment of COPD. Available at http://investor.theravance.com/releasedetail.cfm?ReleaseID=789930. Last accessed November 15, 2013.
4. Almirall. Aclidinium and formoterol fixed dose combination for COPD submitted for registration in Europe. Available at http://www.almirall.com/ webcorp2/cda/comunicacion-detalle-noticia.jsp?id=2593. Last accessed November 15, 2013.
5. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187:347-65.
6. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-36.
7. Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449-56.
8. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210-23.
9. Martinez FJ, Boscia J, Feldman G, et al. Fluticasone furoate/vilanterol (100/25; 200/25 mcg) improves lung function in COPD: a randomised trial. Respir Med. 2013;107:550-9.
10. Agusti A, de Teresa L, De Backer W, et al. A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD. Eur Respir J. 2013. doi: 10.1183/09031936.00054213.
11. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013. doi: 10.1183/09031936.00200212.
12. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107:1538-46.
13. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: BLAZE study. Eur Respir J. 2013. doi: 10.1183/09031936.00124013.
14. Vogelmeier CF, Bateman ED, Pallante J, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol/fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1:51-60.
15. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199.
16. Beeh KM, Korn S, Beier J, et al. QVA149 once daily improves exercise tolerance and lung function in patients with moderate to severe COPD: the BRIGHT study. Thorax 2012;67:A147 (Abstract).
17. Maltais F, Singh SJ, Donald A, et al. Effects of a combination of vilanterol and umeclidinium on exercise endurance in subjects with COPD: two randomized clinical trials. Eur Respir J. 2013;P761.
18. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J. 2013;42:636-46.
19. Vestbo J, Anderson J, Brook RD, et al. The study to understand mortality and morbidity in COPD (SUMMIT) study protocol. Eur Respir J. 2013;41:1017-22.